# Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology

## TL;DR

Experts developed a standardized gene panel for pan-cancer genomic screening to improve personalized cancer therapies and diagnostics.

## Contribution

A consensus-based 99-gene panel for pan-cancer sequencing, including TMB, MSI, and mutation types, was established through a Delphi process.

## Key findings

- A final panel of 99 genes was agreed upon for pan-cancer genomic screening.
- High consensus was achieved for including TMB, MSI, and mutation types like structural variations and fusions.
- The panel is applicable to both adult and pediatric tumor types for harmonized diagnostics and therapies.

## Abstract

The Experimental Cancer Medicine Centre (ECMC) Network supports UK-wide access to experimental cancer therapies, many of which require specific genomic alterations. This study aimed to develop expert consensus on essential genes for a pan-cancer sequencing panel, involving subject matter experts (SMEs) from the ECMC Network and the pharmaceutical industry.

A pilot with 8 SMEs graded 526 genes, refining the list to 210. A three-round Delphi process was then used, with SMEs iteratively evaluating each gene. In the final round, SMEs also assessed the inclusion of tumour mutational burden (TMB), microsatellite instability (MSI), and mutation types (structural variations, copy number variations, and/or fusions).

Consensus was reached on a final panel of 99 genes applicable across multiple cancers. High agreement was also achieved for including TMB, MSI, and screening for structural variations, copy number variants, and fusions. The panel is intended for both adult and paediatric tumour types.

This consensus-based gene panel offers a standardised approach to pan-cancer genomic screening. It supports harmonised diagnostics and could improve patient access to personalised therapies and research trials across clinical and NHS settings.